Literature DB >> 30419200

Achieving high value in the surgical approach to hysterectomy.

James L Whiteside1, Carson T Kaeser2, Beri Ridgeway3.   

Abstract

Value-based care, best clinical outcome relative to cost, is a priority in correcting the high costs for average clinical outcomes of health care delivery in the United States. Hysterectomy represents the most common and identifiable nonobstetric major surgical procedure among women. Surgical approaches to hysterectomy in the United States have changed in recent decades. For benign indications, clinical evidence identifies the superiority of vaginal hysterectomy over all other routes. These conclusions rest on clinical outcomes; however, cost differentials also exist across hysterectomy approaches, with the vaginal approach consistently incurring the lowest overall costs. Taken together, vaginal hysterectomy has the highest value, whereas the robotic (given high costs) and abdominal approaches (given less favorable clinical outcomes) have less value. Traditional laparoscopic hysterectomy holds an intermediate value. Increasing the use of high-value hysterectomy approaches can be achieved by adopting multimodal strategies, with changes in the payment models being the most important.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30419200     DOI: 10.1016/j.ajog.2018.11.124

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Healthcare and Indirect Cost of the Laparoscopic vs. Vaginal Approach in Benign Hysterectomy.

Authors:  María Ángeles Martínez-Maestre; Francisco Jódar-Sánchez; Ana María Calderón-Cabrera; Carmen González-Cejudo; José Manuel Silván-Alfaro; Lidia María Melero-Cortés
Journal:  JSLS       Date:  2022 Jul-Sep       Impact factor: 1.789

2.  In Reply.

Authors:  John B Gebhart; Jennifer J Schmitt; Mary V Baker; John A Occhino; Michaela E McGree; Amy L Weaver; Jamie N Bakkum-Gamez; Sean C Dowdy; Kalyan S Pasupathy
Journal:  Obstet Gynecol       Date:  2020-08       Impact factor: 7.623

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.